Table 2:

Treatment characteristics (during intervention period outside of temporary suspensions)

Variable	Lower Platelet Transfusion Strategy n=25	Higher Platelet Transfusion Strategy n=25	p-value
Anticoagulation Strategies
Initial agent			0.491
Heparin	24/25 (96%)	23/25 (92%)
Bivalirudin	0/25 (0%)	2/25 (8%)
None	1/25 (4%)	0/25 (0%)
Heparin as initial agent
Initial bolus dose (IU/kg)	100 (54;100)	100 (50;100)	0.402
Initial infusion rate (IU/kg/hr)	20 (10;20)	20 (15;22)	0.482
Average highest anti-Xa level (units/mL)	0.4 (0.3;0.6)	0.5 (0.4;0.7)	0.172
Average lowest anti-Xa level (units/mL)	0.3 (0.2;0.4)	0.4 (0.3;0.5)	0.092
Bivalirudin as initial agent
Initial bolus dose (IU/kg)	none	0.1 (0.0;0.1)
Initial infusion rate (IU/kg/hr)	none	0.2 (0.2;0.3)
Platelets
Received ≥ 1 platelet transfusion	11/25 (44%)	17/25 (68%)	0.151
Time from randomization to first plt tx (hrs)	45.2 (8.6;84.0)	5.7 (2.8;22.3)	0.062
Transfusions per intervention day	0.0 (0.0;0.5)	0.7 (0.0;1.2)	0.112
Transfusion dose (mL/kg/day)	0.0 (0.0;8.4)	7.4 (0.0;16.6)	0.112
Received at least 1 whole blood derived plt tx	1/11 (9%)	1/17 (6%)	1.001
Cryoprecipitate
Received ≥ 1 cryoprecipitate transfusion	2/25 (8%)	6/25 (24%)	0.251
Transfusions per intervention day	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.132
Transfusion dose (mL/kg/day)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.152
Prothrombin complex concentrate
Received ≥ 1 PCC transfusion	0/25 (0%)	0/25 (0%)	1.001
Red blood cells
Received ≥ 1 red blood cell transfusion	19/25 (76%)	19/25 (76%)	1.001
Transfusions per intervention day	0.4 (0.1;0.6)	0.3 (0.1;0.7)	0.802
Transfusion dose (mL/kg/day)	4.7 (0.5;9.1)	4.5 (0.5;10.0)	0.832
Plasma
Received ≥ 1 plasma transfusion	6/25 (24%)	5/25 (20%)	1.001
Transfusions per intervention day	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.592
Transfusion dose (mL/kg/day)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.572

Results are presented as median and interquartile range, or number and percentage, as appropriate. PCC, prothrombin complex concentrate.

¹Fisher’s exact test and

²Wilcoxon rank-sum test.